Modulation of Immune Cell Subsets by Hepatitis C Virus (HCV) and Antiviral Therapy in Early Virologic Response in HCV Genotype 4-Infected Patients with Compensated Liver Disease

Sahar Essa\textsuperscript{a}, Raja’a Al-Attiyah\textsuperscript{a}, Iqbal Siddique\textsuperscript{b,c}, Widad Al-Nakib\textsuperscript{a}

\textsuperscript{a}Department of Microbiology, Faculty of Medicine, \textsuperscript{b}Department of Medicine, Faculty of Medicine, Kuwait University, \textsuperscript{c}Thunayan Al-Ghanim Gastroenterology Center, Al-Amiri Hospital, Kuwait.

Address all correspondence to:

Dr. Sahar Essa
Dept of Microbiology, Faculty of Medicine
Kuwait University
PO Box 24923, Safat13110
Kuwait
Tel: +965-99610095
Email: sahar@hsc.edu.kw

Running title: Immune Cell Subsets in Chronic HCV Patients

Keywords: Immunophenotyping • Immune cell subsets • Hepatitis C virus
Highlights of the Study

- This study shows that chronic hepatitis C virus infection is associated with immunomodulation of immune cell subsets.
- Immunomodulation of immune cell subsets by pegylated interferon-α/ribavirin therapy is essential for generating an efficient immune response to eliminate hepatitis C virus infection.
- Pegylated interferon-α/ribavirin therapy facilitates the enhancement of cytotoxic T cells and natural killer-T cells, and the reduction in B cells, activated T cells and T regulatory cells.
Abstract

**Background:** Resolution of chronic hepatitis C virus (HCV) infection requires a complicated interaction between immune cell subsets. The effect of antiviral therapy on immune cell subsets remains to be defined. This study aimed to investigate the absolute count of certain immune cell subsets during therapy with pegylated interferon-α and ribavirin (PegIFN/RBV). **Materials and Methods:** Sixty HCV genotype 4-infected patients with compensated liver disease were treated with PegIFN/RBV therapy for 52 weeks. Efficacy was measured by studying the early virologic response (EVR) at post-therapy week 12. Absolute counts of mature T cells, T helper cells, T cytotoxic cells, activated T cells, Natural Killer (NK) cells, Natural Killer/T (NKT) cells, B cells, T regulatory cells (Treg) and the ratio of T helper to T cytotoxic cells were longitudinally analyzed by flow cytometry throughout the treatment and follow-up course. **Results:** Of the 60 genotype 4-infected subjects, 39 (65%) had EVR, and 21 (35%) were non-EVR patients. For the first part of this study there were significantly lower mean absolute count values of mature T, T cytotoxic, B, and NKT cells. Also, we detected statistically significantly lower mean values for the percentages of T cytotoxic, NKT, Treg, and activated T cells of HCV-infected patients at baseline values when compared with healthy subjects. After the initiation of PegIFN/RBV therapy, frequencies of T helper cells, activated T cells, Treg cells, B cells and T helper : T cytotoxic ratio were found to be significantly lower in EVR patients when compared to non-EVR patients ($p < 0.05$). In contrast, frequencies of T cytotoxic and NKT cells were significantly increased in EVR patients when compared to non-EVR patients ($p < 0.05$). **Conclusion:** These results suggest a pattern of higher levels of T cytotoxic and NKT cells, and lower levels of T helper, activated T, Treg, and B cell populations in patients who respond favorably to Peg-IFN/RBV therapy.
Introduction

Hepatitis C virus (HCV) has significant capability to establish chronicity, as 70 – 80% of infected individuals fail to clear the virus and develop chronic hepatitis C infection. Complex host-viral interactions largely determine the clinical outcomes of HCV infection, ranging from resolution to chronic viral infection [1]. Impairment of T cell responses appears to be the major cause for failure to clear HCV in infected individuals [2 - 4]. HCV-specific T cell responses are essential elements in controlling HCV infection. Acute HCV infection associated with resolution of the infection is accompanied by strong, broad and sustained CD4+ and CD8+ T cell responses, whereas chronic infections are characterized by weak, transient responses [2 - 4].

Several immune cell subsets play important roles in the pathogenesis, progression, and treatment outcomes of HCV infection [1 - 4]. Previous studies documented a strong and long-lasting HCV-specific CD4+ T cell response after PegIFN/RBV therapy in chronically HCV-infected patients [5]. Others suggested a strong association with the induction, expansion, and/or recirculation of HCV-specific T cytotoxic cells after IFN therapy in chronically HCV-infected patients and clearance of HCV infection [6]. Moreover, persistence of HCV infection persistence has been associated with a partial stimulation of B lymphocytes [7]. A sustained response to PegIFN/RBV therapy has been reported to be associated with increased levels and/or activation of natural killer (NK) and natural killer/T (NKT) cells and [8].

One of the critical factors contributing to the dysfunctional T cell immune responses during HCV infection include active suppression by T regulatory cells (Treg) due to high viral load [9]. Previous studies have identified an increase in the proportions of Treg cells in peripheral blood and liver of chronically HCV-infected patients [10]. PegIFN/RBV used to be the standard of care therapy for chronic HCV infection for several years [9], and PegIFN/RBV therapy has been shown result in a decline in Treg cells with fractional recovery of the damaged immune response [10, 11].
Screening of multiple cellular markers of peripheral blood leukocytes may help us understand the immunopathogenesis of the disease and predict responses to Peg-IFN/RBV. We hypothesized that the absolute counts change of immune cell subsets associate with viral load decline following PegIFN/RBV therapy and participates in the resolution of HCV infection in chronically infected patients. To test this hypothesis, we studied the absolute counts of peripheral mature T cells, T helper cells, T cytotoxic cells, B cells, NK cells, NKT cells, Treg cells and activated T cells to ascertain the relationship between absolute counts changes and effectiveness of PegIFN/RBV therapy in patients with early virological response (EVR).

**Materials and Methods**

*Patients and Treatment*

The sample size obtained by statistical power analysis is 65 subjects assuming a 95% rate of change of HCV infection, 95% confidence interval and 0.05 as the maximum accepted error. A total of 67 patients aged 21 and above with chronic HCV infection were recruited for this study. Patients were either hospitalized or had presented for follow-up examination in Al-Amiri Hospital, Kuwait from October 2014 to September 2017. The baseline clinical data of recruited subjects are shown in Table 1. A diagnosis of chronic hepatitis was made if the following criteria were present after follow-up for 26 weeks: significant and persistent symptoms, fluctuating or persistently elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (> 1.5-fold of normal levels), normal serum albumin and prothrombin time, ultrasonography revealing an enlarged bright texture of liver portal tract thickening and normal spleen. Patients with a history of hepatotoxic drug-intake (amoxicillin-clavulanate, flucloxacillin, erythromycin, diclofenac, sulfamethoxazole/Trimethoprim, isoniazid, disulfiram, Ibuprofen, and flutamide), alcohol-intake, and previous antiviral, immunomodulatory or IFN therapy, or those who were co-infected with hepatitis B virus or HIV were excluded from the study. The
PegIFN/RBV therapy protocol consisted of 180 µg of pegylated IFN-α (Pegasys®; Roche, Germany) given subcutaneously once a week plus ribavirin 1,000 – 1,200 mg/day orally (adjusted to body weight, RBV dose/Kg = 15 mg/kg orally per day in 2 divided doses). All patients received PegIFN/RBV therapy for 12 weeks. Patients who achieved a ≥ 2 log reduction of HCV-RNA at week 12 of PegIFN/RBV therapy compared to baseline level by a quantitative HCV-RNA assay were classified as having achieved EVR. Patients who did not achieve a ≥ 2 log reduction of HCV-RNA after week 12 of PegIFN/RBV therapy were classified as non-EVR [12]. Written informed consent was obtained from all participants. The study protocol was approved by the Ethics Committee of the Health Science Center, Kuwait University, and the Ministry of Health, Kuwait. Blood samples were collected on five occasions from all patients: at baseline, 4, 13, 26 and 52 weeks after the initiation of PegIFN/RBV therapy. 30 healthy subjects matched for sex ratio and mean age with the patient group were included as healthy controls (HC).

Biochemical and Virological Investigations

Serum biochemical investigations (including bilirubin, albumin, ALT, AST, creatine, creatine kinase, and blood urea nitrogen) were measured on an automatic analyzer (Hitachi 7170A; Hitachi Ltd, Tokyo, Japan). Anti-HCV antibody levels were determined using the Architect anti-HCV assay (Abbott Diagnostics, Wiesbaden, Germany). Serum HCV RNA was quantified before the initiation of PegIFN/RBV therapy and at 4, 13, 26 and 52 weeks using a commercial real-time PCR (RT-PCR) kit (Roche Molecular Systems, Inc., Branchburg, NJ). Genotyping of HCV was performed using a second-generation line probe assay (Inno-Lipa II; Innogenetics, Zwijndre, Belgium).

Immunophenotyping by Flow Cytometry

Blood samples were collected in EDTA tubes and processed within two hours of collection. 100 µl of blood was mixed with 10 µl of the CYTO-STAT tetraCHROME CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5 and CYTO-STST tetraCHROME CD45-FITC/CD56-RD1/CD19-ECD/CD3-PC5
murine monoclonal antibody mixtures (Beckman Coulter, USA). These antibody mixtures allowed for the simultaneous identification and enumeration of T cells (total CD3$^+$), T helper cells (CD3$^+$/CD4$^+$), T cytotoxic cells (CD3$^+$/CD8$^+$), B cells (CD19$^+$), natural killer (NK) cells (CD3$^+$/CD56$^+$/CD16$^+$) and NKT cells (CD3$^+$/CD56$^+$/CD16$^+$) lymphocyte populations. The tubes were incubated in the dark for 10 min at room temperature after which lysis of red blood cells, stabilization and fixation of the stained cells were carried out through the addition of Immunoprep kit reagents (Beckman Coulter, USA). The staining of Treg (CD4$^+$/CD25$^+$) cells and activated CD8$^+$ T cells was performed by incubating 100 µl of blood with 10 µl of a mixture anti-CD4-FITC and anti-CD25-PE, or anti-CD8-FITC and anti-CD26-PE antibodies (Beckman Coulter, USA) The tubes were incubated at room temperature in the dark for 15 minutes which was followed by the addition of Immunoprep reagents (Beckman Coulter, USA). This facilitated the measurement of the percentage of CD25$^+$ among CD4$^+$ T cells and the percentage of CD26$^+$ marker among CD8$^+$ T cells, respectively. Analysis of the lymphocyte subsets was made using an FC500 Flow Cytometer (15 mW) (Beckman Coulter Electronics, USA). The values were determined as percentages of all the parameters. Absolute values of the lymphocyte subsets (the number of cell/µl) were determined via the addition of flow count fluorospheres to the stained blood. A fluorescence gating strategy using CD45$^+$ vs side scatter was carried out. Internal quality assurance was performed using optical alignment beads and Immunotrol control cells and compensation reagents were used to eliminate bleed through fluorescence. Data analysis was performed using Coulter tetraONE SYSTEM software and System II software.

**Statistical Analysis**

Data management, analysis, and graphical presentation were carried out using the computer software ‘Statistical Package for Social Sciences, SPSS version 24.0’ (IBM Corp, Armonk, NY, USA). The descriptive statistics for all the quantitative clinical variables are presented as mean ± standard deviation (SD). General Linear Model (GLM) was applied for repeated measures to test the main effects within
and between follow-up weeks, as well as for EVR and non-EVR. Non-parametric Wilcoxon Signed test was used to compare volume levels between different follow-up periods, and the Kolmogorov-Smirnov test for comparison between EVR and non-EVR. Pearson correlation tests were performed for correlation analysis. The two-tailed probability value $p < 0.05$ was considered statistically significant.

**Results**

**Baseline Patient Characteristics**

Out of the total number of HCV-infected patients tested ($n = 67$), the majority of those patients ($n = 60, 89\%$) had genotype-4; thus, the statistical analysis was possible only for patients with genotype-4 (Table 1). The data of immune cell subsets for patients with other genotypes (1 and 3) could not be statistically evaluated because of the small numbers.

**Immune Cell Subsets in Untreated HCV-infected Patients and Healthy Subjects**

There were significantly lower mean absolute count values of mature T cells (Fig. 1a, $p < 0.01$), T cytotoxic cells (Fig. 1c, $p < 0.001$), B cells (Fig. 1d, $p < 0.01$), and NKT cells (Fig. 1f, $p < 0.001$) detected in the peripheral blood of HCV-infected patients at baseline values when compared with HC. Despite the lower mean absolute count values of NK cells and T helper cells of HCV-infected patients, no statistically significant differences were detected when compared with HC (Fig. 1b and 1e, $p > 0.05$). We further analyzed the percentages of mature T cells, T helper cells, T cytotoxic cells, B cells, NK cells, NKT cells, Treg cells (CD4$^+CD25^+$), activated T cells (CD8$^+CD26^+$) and the ratio of T helper cells to T cytotoxic cells (CD4$^+$: CD8$^+$) populations of the HCV-infected patients compared to HC (Fig. 2). Statistically significant lower mean values were detected for the percentages of T cytotoxic cells (Fig. 2c, $p < 0.05$), NKT cells (Fig. 2f, $p < 0.001$), Treg cells (Fig. 2j, $p < 0.001$) and activated T cells (Fig. 2h, $p < 0.01$) for HCV-infected patients when compared with HC. However, there were no statistically significant differences in the mean values of percentages for mature T cells (Fig. 2a), T helper cells (Fig.
2b), B cells (Fig. 2d), NK cells (Fig. 2e) and T helper cells: T cytotoxic cells ratio (Fig. 2i) of HCV-infected patients when compared with HC (p > 0.05).

**Correlation between Absolute Counts and Percentages of Immune Cell Subsets and HCV RNA Levels in EVR Patients**

The relationship between the absolute counts and/or the percentages of various immune cell subsets with the HCV replication (represented by HCV RNA levels) was investigated in the EVR patients at baseline, 4, 13, 26 and 52 weeks after the initiation of the PegIFN/RBV therapy. The percentages of B cells after 4 weeks of PegIFN/RBV therapy revealed a positive correlation with HCV RNA levels (R² linear = 0.06, p = 0.04) (data not shown). A negative correlation was demonstrated between the percentages of Treg cells and HCV RNA levels at baseline values (R² linear = 0.116, p = 0.02). Such a correlation was not detected after treatment. Other immune cell subsets did not show any correlation with HCV RNA levels after the initiation of PegIFN/RBV therapy in the EVR patients (p > 0.05, data not shown).

**Effect of PegIFN/RBV Therapy on Absolute Counts and Percentages of Immune Cell Subsets in HCV-infected Patients (EVR vs. On-EVR)**

Data for the immunophenotyping of immune cell subsets for the genotype-4, EVR patients (n = 39) vs. non-EVR patients (n = 21) are presented in Fig. 3 and 4. Although the absolute counts of mature T cells were slightly lower in EVR in comparison to non-EVR patients, there was no significant change in response to PegIFN/RBV therapy (Fig. 3a, p > 0.05). In contrast, the percentages of mature T cells were slightly higher, but also with no significant change in response to the PegIFN/RBV therapy (Fig. 4a, p > 0.05). As for the absolute counts of T helper cells, a continuous decline was detected after initiation of PegIFN/RBV therapy in EVR patients until 26 weeks with a significant difference at 4 weeks of PegIFN/RBV therapy (Fig. 3b, p < 0.05). As for the percentages of T helper cells a significant difference between the two groups was detected at 4 and 13 weeks of PegIFN/RBV therapy (Fig. 4b, p < 0.05).
Furthermore, the absolute counts of T cytotoxic cells were slightly higher in EVR patients after initiation of PegIFN/RBV therapy, with no significant difference (Fig. 3c, $p > 0.05$). Also, higher percentages mean values for T cytotoxic cell were detected in EVR than non-EVR patients with significant differences at baseline, 4 and 13 weeks after the initiation of PegIFN/RBV therapy (Fig. 4c, $p < 0.01$, $p < 0.01$, $p < 0.05$ respectively). On the other hand, B cell absolute counts and percentages continued to show a decrease in EVR patients with a significant decline at 26 and 52 weeks after the initiation of the PegIFN/RBV therapy (Fig. 3d, $p < 0.01$ and $p < 0.05$ respectively) and (Fig. 4d, $p < 0.001$). The absolute counts and percentages of NK cells for EVR patients started with significantly lower values at baseline (Fig. 3e and 4e, $p < 0.001$ each). Then after the initiation of the PegIFN/RBV therapy, continued to increase but with no significant differences (Fig. 3e and 4e, $p > 0.05$). As for the absolute counts of NKT cells, there was a decline over the weeks of PegIFN/RBV therapy for both groups of patients with no significant difference (Fig. 3f, $p > 0.05$). Furthermore, percentages of NKT cells for EVR in comparison with non-EVR patients were higher after the initiation of PegIFN/RBV therapy with a significant difference at 4 weeks, then it showed a sharp decrease at 52 weeks of therapy with no statistical difference (Fig. 4f, $p < 0.05$ and $p > 0.05$ respectively). Interestingly, the percentages of Treg cells revealed a remarkable decrease in EVR in comparison with non-EVR patients with a highly significant difference at 4, 26 and 52 weeks after the initiation of PegIFN/RBV therapy (Fig. 4j, $p < 0.001$). Also, the percentages of activated T cells for EVR in comparison with non-EVR patients showed a significant increase at baseline values, then the values increased for the non-EVR patients with a significant difference between the two groups at 13 and 26 weeks after the initiation of PegIFN/RBV therapy (Fig. 4h, $p < 0.01$). As for the ratio of T helper: T cytotoxic cells, it was significantly lower for EVR in comparison to non-EVR patients at baseline values (Fig. 4i, $p < 0.01$). After the initiation of PegIFN/RBV therapy, it continued this way until 26 weeks with a significant difference at 4 and 13 weeks (Fig. 4i, $p < 0.001$ and $p < 0.05$ respectively).
**Discussion**

This study aimed at carrying out a comparative analysis of immune cell subsets in the peripheral blood of chronically HCV-infected patients during the course of PegIFN/RBV therapy in an attempt to understand the mechanism of action of the therapy. To fulfill this objective, we measured the absolute counts and/or percentages of mature T, T helper, T cytotoxic, B, NK, NKT, Treg, T helper:T cytotoxic ratio, and activated T cells over a period of 52 weeks in EVR patients before and during PegIFN/RBV therapy. EVR was used as a clinical marker to monitor the progress of treatment/disease.

We observed that the absolute counts and/or percentages of mature T, T cytotoxic, NKT, Treg, T activated, and B cells were significantly reduced in chronically HCV-infected patients when compared to HC. Earlier studies identified variations in the proportion of T subsets, NK, and NKT cells in peripheral blood of chronically HCV-infected patients at baseline values [8, 9-11] which could indicate the importance of these immune cell subsets in the persistence of HCV infection. An interesting aspect of chronic HCV infection is the development of weak T helper and T cytotoxic responses caused either by a primary T cell failure or by T cell exhaustion [4]. Moreover, changes in the T helper:T cytotoxic ratio may cause a failure in the coordination between them, which could result in chronic persistent infection [13]. The other interesting observation made in the present study is that the percentages of Treg cells in the HCV-infected patients were significantly lower when compared to HC, which is inconsistent with a previous study [9]. Mechanisms of T cell dysfunction might include the action of Treg cells due to impaired priming of virus-specific T cells and suppression by inhibitory cytokines [14]. These variations in Treg cells proportion may play an essential role in HCV persistence [9, 11].

Earlier studies have reported low NK cell quantity and altered NK functions in chronic HCV infection [2, 8, 15]; these perturbations in levels may contribute to a failure to clear HCV infection. The reason for the decreased absolute count of NK and NKT cells in chronically HCV-infected patients is currently
unidentified, although possible explanations may include increased death or turnover, or reduced production of these cells [16].

The significant decrease in the absolute counts and/or the percentages of immune cell subsets in chronically HCV-infected patients, when compared to HC, may represent an immunomodulatory effect of HCV infection on these cell populations as suggested previously [17]. Also, this imbalance in the immune cell subsets could facilitate the persistence of HCV infection [15]. It is also possible that this represents an immunological escape mechanism by HCV, which appears to survive in the presence of an impaired immune response [17].

Interestingly, we detected a significant increase in the percentages of T cytotoxic cells (at 4 and 13 weeks) in the EVR in comparison to non-EVR patients. On the other hand, the percentages of T helper (at 4 and 13 weeks), T activated (at 13 and 26 weeks), and the ratio of T helper:T cytotoxic (at 4 and 13 weeks) showed a significant decrease in EVR in comparison to non-EVR patients. In addition, when the absolute counts of T helper cells of the EVR and non-EVR patients were compared, the EVR patients showed a significant decrease after 4 weeks after the initiation of PegIFN/RBV therapy. This could be due to ‘immunological exhaustion’ of circulating T helper cells. Some researchers suggest that the immune system tries to eradicate the HCV infection during the initial stages of infection and treatment. Subsequently, some functional responses might be damaged [18]. Although the exact effective mechanisms implemented by T cytotoxic cells to clear HCV still remain to be revealed, a previous study by Spangenberg et al. [19] found that a lasting and comprehensive T cytotoxic response is essential for effective elimination of HCV infection. A recent study indicated that antiviral IFN-free therapy mediated restoration of T cytotoxic cells may restore T cytotoxic cell impaired function in chronically HCV-infected patients [6, 20]. Another study showed that PegIFN/RBV therapy is associated with an enhanced HCV-specific cytotoxic T cell response, which leads to a positive correlation between the induction of PegIFN/RBV therapy and HCV-specific T cytotoxic responses in chronically HCV-infected patients.
Therefore, we speculate that PegIFN/RBV therapy may associate with immune stimulation that could repair certain immune cell subsets by supporting clonal extension and cellular development [22] or by reducing T cell exhaustion by reducing viral load [23]. The functional restoration of these immune cell subsets might be considered as an early prognostic marker of the effective immune response [24]. Restoration of levels of T cytotoxic cells could be the initial step in the restoration of effector cell function that might happen alongside the PegIFN/RBV therapy.

We detected a negative correlation between the percentages of Treg cells and HCV RNA at baseline. Such a correlation was not detected after treatment. Several studies have demonstrated a positive correlation between increased Treg cell counts and chronic HCV infection [10, 25, 26]; this discrepancy may be due to differences in study populations, as we compared genotype-4 EVR and non-EVR patients. Cabrera et al. [10] and Sugimoto et al. [25] compared untreated spontaneously recovered HCV subjects and chronically HCV-infected patients whereas Ebinuma et al. [26] compared untreated HCV-infected and uninfected individuals. After the initiation of PegIFN/RBV therapy, the percentages of Treg cells showed a significant decrease in EVR in comparison to non-EVR patients at 4, 26 and 52 weeks which is consistent with a previous study [11]. This result may suggest a possible role for Treg cells in the virological response to PegIFN/RBV therapy. Hoa et al [11] reported that the frequency of Treg cells was reduced 4 weeks after the initiation of PegIFN/RBV therapy, and continued to decrease during the follow-up period in subjects with rapid virological response. In contrast, another study revealed that effective PegIFN/RBV therapy is associated with an increase in Treg cells with a slight recovery of the damaged immune response in non-responder patients [7].

Interestingly, we observed a positive correlation between HCV viral load in EVR patients and the percentages of B cells 4 weeks after initiation of PegIFN/RBV therapy. However, the absolute counts of B cells, as well as B cell percentages decreased significantly at 26 and 52 weeks in EVR patients after the initiation of PegIFN/RBV therapy. Amati et al. [27] described higher absolute counts of B cells in
poor responders than in responders at the end of the PegIFN/RBV therapy, which is similar to our observation. Amati et al suggest that this is attributable to higher levels of anti-lactoferrin (LF) antibodies in non-responders than in the responders, and that these autoantibodies might affect the antiviral activity of LF and block LF binding to lipopolysaccharides (LPS). Such interactions would obstructs the binding of LPS to LPS binding protein, thus preventing LPS fixation to CD14+ eventually leading to a reduced release of proinflammatory cytokines.

We also observed that the absolute counts and percentages of NK cells were continuously increased but with no significant difference between the EVR and non-EVR patients after the initiation of PegIFN/RBV therapy. This could be due to increased dynamism of NK cells [16]. He et al. [28] suggested that IFN-α enhances the expression of CD100 on NK cells which plays an important role in promoting NK function in patients with chronic hepatitis C. On the other hand, we noted a significant increase in the percentages of NKT cells shortly after the initiation of PegIFN/RBV therapy, i.e. at 4 weeks. The reason for this increase remains unclear but it may reflect the importance of NKT cells in the clearance of HCV infection in EVR in comparison to non-EVR patients which led to the recovery of NKT cells population to normal proportions [8, 29]. NKT cells could inhibit HCV replication via the secretion of IFN-γ thus playing vital roles in antiviral defenses [4]; their antiviral activity have been shown to be associated with the consequence of acute HCV infection [3] and the efficacy of IFN-α treatment in chronically infected HCV patients [8, 29]. Interestingly, the activation of NKT cells by α-galactosylceramide, a novel synthetic glycolipid, has been shown to reduce HCV viral replication, as determined by reduction in viral load during chronic HCV infection in chimpanzees [30]. Thus, our findings suggest that stimulation of NKT cells by the PegIFN/RBV therapy may be necessary for the resolution of chronic HCV infection.

Conclusion
Our working hypothesis was that antiviral therapy in EVR patients leads to the production of effective immune cell subsets which can aid in viral clearance during PegIFN/RBV therapy. Data presented in this study suggests that chronic HCV infection has an immunomodulatory effect on immune cell subsets. Our results indicate that the enhancement of T cytotoxic, NKT cells and the reduction of B cells, Treg, and T activated cells by PegIFN/RBV therapy may facilitate the restoration of an effective immune response leading to HCV resolution. Future studies should consider immunomodulatory therapeutic regimens that aim to enhance the antiviral response by improving the activity of cytotoxic T cells and NKT cells while inhibiting B cells and Treg cells in chronically HCV-infected patients, in particular non-EVR patients, for therapy-related viral resolution. Limitations in this study include the fact that immune cell subsets were collected from peripheral blood samples; it would be more relevant to analyze these immune cell subsets in the local environment, i.e. in the liver. Furthermore, the bulk of participants were genotype-4; the availability of other genotypes would have allowed enhanced comparative results.
References

1. Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C virus infection: Host–virus interaction and mechanisms of viral persistence. Cells. 2019;8:376.

2. Golden-Mason L, Castelblanco N, O'Farrelly C, Rosen HR. Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection. J Virol. 2007; 81:9292-9298.

3. Ye L, Wang X, Wang S, Wang Y, Song L, Hou W, et al. CD56+ T cells inhibit hepatitis C virus replication in human hepatocytes. Hepatol. 2009;49:753-762.

4. Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin N Am. 2015; 44:717–734.

5. Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, et al. Acute hepatitis C Study Group. Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin. Hepatol. 2014;59:2101-2109.

6. Martin B, Hennecke N, Lohmann V, Kayser A, Neumann-Haefelin C, Kukolj G, et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol. 2014;61:538-543.

7. Soldevila B, Alonso N, Martínez-Arconada MJ, Morillas RM, Planas R, Sanmartí AM, et al. A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4+CD25+CD127low/−FoxP3+ T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment. J Viral Hepat 2011;18:384-392.

8. Yamagiwa S, Matsuda Y, Ichida T, Honda Y, Takamura M, Sugahara S, et al. Sustained response to interferon-α plus ribavirin therapy for chronic hepatitis C is closely associated with increased dynamism of intrahepatic natural killer and natural killer T cells. Hepatol Res. 2008;38:664-672.

9. Wang JP, Zhang Y, Wei X, Li J, Nan XP, Yu HT, et al. Circulating Toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C. APMIS 2010;118:261-270.
10. Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatol. 2004;40:1062-1071.

11. Hao C, Zhou Y, He Y, Fan C, Sun L, Wei X, et al. Imbalance of regulatory T cells and T helper type 17 cells in patients with chronic hepatitis C. Immunol. 2014;143:531-538.

12. Deltenre P, Canva V, El Nady M, François C, Castelain S, Dharancy S. A 2-log drop in viral load at 1 month is the best predictor of sustained response in HCV patients with normal ALT: a kinetic prospective study. J Viral Hepat. 2009;16:500-505.

13. Bengsch B, Seigel B, Ruhl M, Timm J, Kuntz M, Blum HE, et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog. 2010; 6:e1000947.

14. Neumann-Haefelin C, Thimme R. Success and failure of virus-specific T cell responses in hepatitis C virus infection. Dig Dis. 2011;29:416-422.

15. Lunemann S, Malone DF, Hengst J, Port K, Grabowski J, Deterding K, et al. Compromised function of natural killer cells in acute and chronic viral hepatitis. J Infect Dis 2014;209:1362-1373.

16. Morishima C, Paschal DM, Wang CC. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatol. 2006;43:573-580.

17. Dimitropoulou D, Karakantza M, Tsamandas AC, Mouzaki A, Theodorou G, Gogos CA. T-lymphocyte subsets in peripheral blood and liver tissue of patients with chronic hepatitis B and C. In Vivo. 2011;25:833-840.

18. Brenndörfer ED, Brass A, Karthe J, Ahlén G, Bode JG, Sällberg M. Cleavage of the T cell protein tyrosine phosphatase by the hepatitis C virus nonstructural 3/4A protease induces a Th1 to Th2 shift reversible by ribavirin therapy. J Immunol. 2014; 192:1671-1680.
19. Spangenberg HC, Viazov S, Kersting N, Neumann-Haefelin C, McKinney D, Roggendorf M, et al. Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. Hepatol. 2005;42:828-837.

20. Rehermann B, Bertoletti A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatol. 2015;61:712-721

21. Larrubia JR, Lokhande MU, Moreno-Cubero E, García-Garzón S, Miquel J, Parra-Cid T, et al. HCV-specific CD8+ cell detection at week 12 of chronic hepatitis C treatment with PEG-interferon-α2b/ribavirin correlates with infection resolution. Cell Immunol. 2013;286:31-38.

22. Velazquez VM, Uebelhoer LS, Thapa M, Ibegbu CC, Courtney C, Bosinger SE, et al. Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development. Hepatol. 2015;61:843-856.

23. Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol. 2004;78:5707-5719.

24. Humphreys IS, von Delft A, Brown A, Hibbert L, Collier JD, Foster GR, et al. HCV genotype-3a T cell immunity: specificity, function and impact of therapy. Gut. 2012;61:1589-15899.

25. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatol. 2003;38:1437-1448.

26. Ebinuma H, Nakamoto N, Li Y, Price DA, Gostick E, Levine BL, et al. Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol. 2008;82:5043-5053.

27. Amati L, Cozzolongo R, Manghisi OG, Cuppone R, Pellegrino NM, Caccavo D, et al. The immune responsiveness in hepatitis C virus infected patients: effects of interferon-alpha/ribavirin combined
treatment on the lymphocyte response with special reference to B cells. Curr Pharm Des. 2004; 10:2093-2100.

28. He Y, Guo Y, Fan C, Lei Y, Zhou Y, Zhang M, et al. Interferon-α-enhanced CD100/Plexin-B1/B2 interactions promote natural killer cell functions in patients with chronic hepatitis C virus infection. Front Immunol. 2017; 8:1435.

29. Nakamura I, Asano T, Asabe S, Ando M, Sano T, Miyata Y, et al. Restoration of natural killer cell activity by pegylated interferon-alpha/ribavirin therapy in chronic hepatitis C patient. Hepatol Res. 2015; 45:107-112.

30. Mehta AS, Gu B, Conyers B, Ouzounov S, Wang L, Moriarty RM, et al. α-Glycosylceramide and novel synthetic glycolipids directly induce the innate host defense pathway and have direct activity against hepatitis B and C viruses. Antimicrob Agent Chemother. 2004; 48:2085–2090.
Figure legends

Figure 1. Boxplots of interquartile range of absolute counts for cellular subsets in HCV-infected patients and HC. Mature T cells (a), T helper cells (b), T cytotoxic cells (c), B cells (d), NK cells (e) and NKT cells (f) at baseline values. *p < 0·05, **p < 0·01, ***p < 0·001 refers to the statistical differences.

Figure 2. Boxplots of Interquartile range of percentages for immune cell subsets in HCV-infected patients and HC. Mature T cells (a), T helper cells (b), T cytotoxic cells (c), B cells (d), NK cells (e) and NKT cells (f), Treg cells (j), activated T cells (h) and CD4+:CD8+ ratio (i), at baseline values. *p < 0·05, **p < 0·01, ***p < 0·001 refers to the statistical differences.

Figure 3. Mean values of absolute counts for EVR and non-EVR patients. Mature T cells (a), T helper cells (b), T cytotoxic cells (c), B cells (d), NK cells (e) NKT cells (f), at baseline values and during the course of PegIFN/RBV therapy (at 4, 13, 26 and 52 weeks). Error bars illustrate the standard deviations. *p < 0·05, **p < 0·01, ***p < 0·001 refers to the statistical differences among EVR and non-EVR patients.

Figure 4. Mean values of percentages for EVR and non-EVR patients. Mature T cells (a), T helper cells (b), T cytotoxic cells (c), B cells (d), NK cells (e) NKT cells (f), Treg cells (j), activated T cells (h) and CD4+:CD8+ ratio (i), at baseline values and during the course of PegIFN/RBV therapy (at 4, 13, 26 and 52 weeks). Error bars illustrate the standard deviations. *p < 0·05, **p < 0·01, ***p < 0·001 refers to the statistical differences among EVR and non-EVR patient.
FIG. 1
FIG. 2
FIG. 3
FIG. 4
Table 1: Demographic and clinical characteristics of subject groups.

| Parameters                              | HC     | EVR patients | Non-EVR patients |
|-----------------------------------------|--------|--------------|------------------|
| No.                                      | 30     | 46           | 21               |
| Sex (males/females)                     | 9/21   | 26/20        | 13/8             |
| Age (years) ± SD                        | 29 ± 4.2 | 30 ± 5.4   | 32 ± 7.4         |
| ALT level (U/l) ± SD                    | 22 ± 7.55 | 78 ± 34.55 | 68 ± 14.61       |
| At week 12                              | N.A.   | 36 ± 14.76   | 52 ± 18.40       |
| AST level (U/l) ± SD                    | 18 ± 10.5 | 72.5 ± 33.2 | 79.5 ± 44.2      |
| At week 12                              | N.A.   | 35 ± 12.1    | 61 ± 29.3        |
| HCV RNA level (log10 copies/ml) ± SD    | N.A.   | 5.94 ± 0.53  | 6.24 ± 0.46      |
| At week 12                              | N.A.   | 1.54 ± 0.65  | 5.8 ± 0.83       |
| HCV genotype (4/3/1)                    | N.A.   | 39/4/3       | 21/0/0           |

Data are shown as mean ± SD

Abbreviations: HC healthy control; SD standard deviation, HCV hepatitis c virus, EVR early virologic response, N.A. not applicable, ALT alanine aminotransferase, AST aspartate aminotransferase.